These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

692 related items for PubMed ID: 30661513

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).
    Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN.
    J Urol; 2021 May; 205(5):1421-1429. PubMed ID: 33356445
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
    Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN.
    J Urol; 2020 Aug; 204(2):316-324. PubMed ID: 32068484
    [Abstract] [Full Text] [Related]

  • 5. Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.
    Staskin D, Frankel J, Varano S, Kennelly M, Newman DK, Rosenberg MT, Shortino DD, Jankowich RA, Mudd PN.
    Int J Clin Pract; 2022 Aug; 2022():6475014. PubMed ID: 35685566
    [Abstract] [Full Text] [Related]

  • 6. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K.
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.
    Shi H, Chen H, Zhang Y, Cui Y.
    Neurourol Urodyn; 2020 Jun; 39(5):1255-1263. PubMed ID: 32421908
    [Abstract] [Full Text] [Related]

  • 9. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A.
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder.
    Su S, Liang L, Lin J, Liu L, Chen Z, Gao Y.
    Medicine (Baltimore); 2021 Feb 05; 100(5):e23171. PubMed ID: 33592817
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term safety and efficacy of the novel β3 -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study.
    Yoshida M, Kakizaki H, Takahashi S, Nagai S, Kurose T.
    Int J Urol; 2018 Jul 05; 25(7):668-675. PubMed ID: 29752752
    [Abstract] [Full Text] [Related]

  • 14. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E.
    Eur Urol; 2020 Jan 05; 77(1):119-128. PubMed ID: 31635815
    [Abstract] [Full Text] [Related]

  • 15. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.
    Ohlstein EH, von Keitz A, Michel MC.
    Eur Urol; 2012 Nov 05; 62(5):834-40. PubMed ID: 22695239
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study.
    Varano S, Staskin D, Frankel J, Shortino D, Jankowich R, Mudd PN.
    Drugs Aging; 2021 Feb 05; 38(2):137-146. PubMed ID: 33469832
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
    Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A, YM-905 Study Group.
    BJU Int; 2004 Feb 05; 93(3):303-10. PubMed ID: 14764127
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Vibegron for the Treatment of Overactive Bladder in Women: A Subgroup Analysis From the Double-Blind, Randomized, Controlled EMPOWUR Trial.
    Newman DK, Thomas E, Greene H, Haag-Molkenteller C, Varano S.
    Urogynecology (Phila); 2023 Jan 01; 29(1):48-57. PubMed ID: 36384907
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
    Kennelly MJ, Rhodes T, Girman CJ, Thomas E, Shortino D, Mudd PN.
    Adv Ther; 2021 Nov 01; 38(11):5452-5464. PubMed ID: 34537953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.